Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Phase III Study Showed Two Years of ACTEMRA® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission
Phase III Study Showed Two Years of ACTEMRA® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission
Phase III Study Showed Two Years of ACTEMRA® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission
Submitted by
admin
on October 18, 2009 - 10:57am
Source:
Reuters
News Tags:
Actemra
tocilizumab
rheumatoid arthritis
Genentech
Headline:
Phase III Study Showed Two Years of ACTEMRA® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission
Do Not Allow Advertisers to Use My Personal information
